Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Müllerian hormone cutoff value
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Although increased serum anti-Müllerian hormone (AMH) level has been suggested to be a surrogate marker of polycystic ovarian morphology (PCOM), its association with polycystic ovary syndrome (PCOS) is controversial, and its diagnostic value has not been determined. We aimed to observe the relationship between the AMH level and PCOS phenotypes and to determine the optimal cutoff value of AMH for the diagnosis of PCOS in young Korean women. Methods: We recruited 207 women with PCOS (120 with PCOM and 87 without PCOM) and 220 regular cycling women with normoandrogenemia (100 with PCOM and 120 without PCOM). Subjects underwent testing at a single outpatient visit. Serum AMH level was measured. Results: Women with PCOS had higher serum AMH levels than did regular cycling women with normoandrogenemia (p < 0.05). Women with PCOM had higher serum AMH levels than women without PCOM, regardless of PCOS status (p < 0.05). The optimal AMH cutoff value for the diagnosis of PCOS was 10.0 ng/mL (71% sensitivity, 93% specificity). Serum AMH was an independent determinant of total testosterone after adjustment for age, body mass index, and the number of menses/year (β = 0.31, p < 0.01). An association between AMH and hyperandrogenism was only observed in women with PCOS, and it was independent of the presence of PCOM. Conclusion: The serum AMH level can be useful for the diagnosis of PCOS at any age less than 40 years, and the optimal cutoff value for the diagnosis of PCOS identified in this study of young Korean women was 10.0 ng/mL.
Abstract
Background/Aims: Although increased serum anti-Müllerian hormone (AMH) level has been suggested to be a surrogate marker of polycystic ovarian morphology (PCOM), its association with polycystic ovary syndrome (PCOS) is controversial, and its diagnostic value has not been determined. We aimed to observe the relationship between the AMH level and PCOS phenotypes and to determine the optimal cutoff value of AMH for the diagnosis of PCOS in young Korean women. Methods: We recruited 207 women with PCOS (120 with PCOM and 87 without PCOM) and 220 regular cycling women with normoandrogenemia (100 with PCOM and 120 without PCOM). Subjects underwent testing at a single outpatient visit. Serum AMH level was measured. Results: Women with PCOS had higher serum AMH levels than did regular cycling women with normoandrogenemia (p < 0.05). Women with PCOM had higher serum AMH levels than women without PCOM, regardless of PCOS status (p < 0.05). The optimal AMH cutoff value for the diagnosis of PCOS was 10.0 ng/mL (71% sensitivity, 93% specificity). Serum AMH was an independent determinant of total testosterone after adjustment for age, body mass index, and the number of menses/year (β = 0.31, p < 0.01). An association between AMH and hyperandrogenism was only observed in women with PCOS, and it was independent of the presence of PCOM. Conclusion: The serum AMH level can be useful for the diagnosis of PCOS at any age less than 40 years, and the optimal cutoff value for the diagnosis of PCOS identified in this study of young Korean women was 10.0 ng/mL.
참고문헌 (35)
- Azziz R, "The prevalence and features of the polycystic ovary syndrome in an unselected population", J Clin Endocrinol Metab, 89, pp.2745~2749 (2004)
- Rotterdam ESHRE, "ASRM-Sponsored PCOS Consensus Workshop Group.", Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, 2004, pp.81, 19~25
- Robin G, "Polycystic ovary-like abnormalities (PCO-L) in women with functional hypothalamic amenorrhea", J Clin Endocrinol Metab, 97, pp.4236~4243 (2012)
- Keevil BG., "How do we measure hyperandrogenemia in patients with PCOS?", J Clin Endocrinol Metab, 99, pp.777~779 (2014)
- Weenen C, "Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment", Mol Hum Reprod, 10, pp.77~83 (2004)
- Pigny P, "Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest", J Clin Endocrinol Metab, 88, pp.5957~5962 (2003)
- Sahmay S, "Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome", Eur J Obstet Gynecol Reprod Biol, 170, pp.157~161 (2013)
- Rosenfield RL, "Antimullerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries", Fertil Steril, 98, pp.242~249 (2012)
- Sahmay S, "Diagnosis of polycystic ovary syndrome: AMH in combination with clinical symptoms", J Assist Reprod Genet, 31, pp.213~220 (2014)
- Pinola P, "Anti-Mullerian hormone: correlation with testosterone and oligo-or amenorrhoea in female adolescence in a population-based cohort study", Hum Reprod, 29, pp.2317~2325 (2014)
- Iliodromiti S, "Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data", J Clin Endocrinol Metab, 98, pp.3332~3340 (2013)
- Dewailly D, "Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries", Hum Reprod, 26, pp.3123~3129 (2011)
- Li Y, "Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism", J Assist Reprod Genet, 29, pp.1147~1151 (2012)
- Cui Y, "Age-specific serum antimullerian hormone levels in women with and without polycystic ovary syndrome", Fertil Steril, 102, pp.230~236 (2014)
- Lauritsen MP, "The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone", Hum Reprod, 29, pp.791~801 (2014)
- Escobar-Morreale HF, "Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society", Hum Reprod Update, 18, pp.146~170 (2012)
- Sung YA., "Hyperandrogenism in women: polycystic ovary syndrome", Hanyang Med Rev, 32, pp.197~202 (2012)
- Balen AH, "Ultrasound assessment of the polycystic ovary: international consensus definitions", Hum Reprod Update, 9, pp.505~514 (2003)
- Homburg R, "The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study", Hum Reprod, 28, pp.1077~1083 (2013)
- Koninger A, "Anti-Mullerian hormone:an indicator for the severity of polycystic ovarian syndrome", Arch Gynecol Obstet, 290, pp.1023~1030 (2014)
- Laven JS, "Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age", J Clin Endocrinol Metab, 89, pp.318~323 (2004)
- Piltonen T, "Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome", Hum Reprod, 20, pp.1820~1826 (2005)
- Pigny P, "Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome", J Clin Endocrinol Metab, 91, pp.941~945 (2006)
- Nardo LG, "The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome", Hum Reprod, 24, pp.2917~2923 (2009)
- Eldar-Geva T, "Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism", Hum Reprod, 20, pp.1814~1819 (2005)
- Jonard S, "The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest", Hum Reprod Update, 10, pp.107~117 (2004)
- Durlinger AL, "Regulation of ovarian function: the role of anti-Mullerian hormone", Reproduction, 124, pp.601~609 (2002)
- Chen MJ, "The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome", Hum Reprod, 23, pp.952~957 (2008)
- Wang JG, "Mullerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome", Am J Obstet Gynecol, 196, pp.77~ (2007)
- 황유임, "Can high serum anti-Müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?", Clinical and Experimental Reproductive Medicine, 40(3), pp.135~140 (2013), 대한생식의학회
- Li L, "Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome", Wien Klin Wochenschr, 122, pp.519~524 (2010)
- Tremellen K, "Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan", Aust N Z J Obstet Gynaecol, 55, pp.384~389 (2015)
- Woo HY, "Differences of the association of anti-Mullerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome", Endocr J, 59, pp.781~790 (2012)
- Han X, "Pre-mixing serum samples with assay buffer is a prerequisite for reproducible anti-Mullerian hormone measurement using the Beckman Coulter Gen II assay", Hum Reprod, 29, pp.1042~1048 (2014)
- Carmina E, "Does the level of serum antimullerian hormone predict ovulatory function in women with polycystic ovary syndrome with aging?", Fertil Steril, 98, pp.1043~1046 (2012)